THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
GlobalData on MSN7d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
The median overall survival with Libtayo (cemiplimab) was 12 months, compared to 8.5 months for the control group, which was treated with chemo selected by investigators. The study enrolled women ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer ...
According to the September announcement, a median overall survival of 26 months was seen in the Libtayo treatment group, compared to 13 months in the chemotherapy cohort, and median progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback